Small-Cell Lung Cancer - Pipeline Review, H1 2014


#195045

310pages

Global Markets Direct

$ 2000

In Stock

Small-Cell Lung Cancer - Pipeline Review, H1 2014

Summary

Global Markets Directs, Small-Cell Lung Cancer - Pipeline Review, H1 2014, provides an overview of the Small-Cell Lung Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Small-Cell Lung Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Small-Cell Lung Cancer - Overview 11
Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis 12
Small-Cell Lung Cancer - Therapeutics under Development by Companies 13
Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 18
Small-Cell Lung Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Small-Cell Lung Cancer - Products under Development by Companies 23
Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes 27
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 28
Bristol-Myers Squibb Company 28
Boehringer Ingelheim GmbH 29
Amgen Inc. 30
AstraZeneca PLC 31
Eli Lilly and Company 32
GlaxoSmithKline plc 33
Nektar Therapeutics 34
Merck & Co., Inc. 35
Dainippon Sumitomo Pharma Co., Ltd. 36
Aposense Ltd. 37
ZIOPHARM Oncology, Inc. 38
Millennium Pharmaceuticals, Inc. 39
Novartis AG 40
Astellas Pharma Inc. 41
Nippon Kayaku Co., Ltd. 42
Pfizer Inc. 43
A. Menarini Industrie Farmaceutiche Riunite Srl 44
Onyx Pharmaceuticals, Inc. 45
Bayer AG 46
Alchemia Limited 47
ImmunoCellular Therapeutics, Ltd. 48
Immunomedics, Inc. 49
MEI Pharma, Inc. 50
Critical Outcome Technologies Inc. 51
CytRx Corporation 52
Mologen AG 53
Synta Pharmaceuticals Corp. 54
MabVax Therapeutics, Inc. 55
Spectrum Pharmaceuticals, Inc. 56
Supratek Pharma Inc. 57
Oxford BioTherapeutics Ltd 58
TheRyte Ltd. 59
Celator Pharmaceuticals, Inc. 60
Cerulean Pharma, Inc. 61
OncoMed Pharmaceuticals, Inc. 62
Merrimack Pharmaceuticals, Inc. 63
Neotropix, Inc. 64
Mersana Therapeutics, Inc. 65
Cornerstone Pharmaceuticals, Inc. 66
Omnitura Therapeutics Inc. 67
MolMed S.p.A. 68
Laboratorios Farmaceuticos Rovi, S.A. 69
Sunshine Biopharma, Inc. 70
Recombio 71
Mycenax Biotech Inc. 72
Polaris Group 73
CellAct Pharma GmbH 74
centrose llc 75
Zensun (Shanghai) Sci & Tech Co., Ltd. 76
Inbiopro Solutions Pvt. Ltd. 77
AbbVie Inc. 78
Amgen Astellas BioPharma K.K. 79
Small-Cell Lung Cancer - Therapeutics Assessment 80
Assessment by Monotherapy Products 80
Assessment by Combination Products 81
Assessment by Target 82
Assessment by Mechanism of Action 87
Assessment by Route of Administration 93
Assessment by Molecule Type 95
Drug Profiles 98
amrubicin hydrochloride - Drug Profile 98
ipilimumab - Drug Profile 100
amrubicin hydrochloride - Drug Profile 103
palifosfamide - Drug Profile 105
nintedanib - Drug Profile 107
pravastatin sodium + [carboplatin] + [etoposide] - Drug Profile 109
sabarubicin - Drug Profile 110
alisertib - Drug Profile 112
linsitinib - Drug Profile 115
irinotecan hydrochloride - Drug Profile 117
etirinotecan pegol - Drug Profile 119
NTX-010 - Drug Profile 122
CPI-613 - Drug Profile 124
NGR-hTNF - Drug Profile 126
ganetespib - Drug Profile 129
CRLX-101 - Drug Profile 133
pegargiminase - Drug Profile 135
MK-2206 + selumetinib sulfate - Drug Profile 138
NK-012 - Drug Profile 140
temozolomide - Drug Profile 142
LY-2510924 - Drug Profile 144
IMMU-132 - Drug Profile 145
ardeparin sodium - Drug Profile 146
celecoxib - Drug Profile 148
CAP-7.1 - Drug Profile 149
rilotumumab - Drug Profile 151
ganitumab - Drug Profile 153
carfilzomib - Drug Profile 156
TF-2 - Drug Profile 159
BAY-1000394 - Drug Profile 161
taladegib - Drug Profile 163
OMP-59R5 - Drug Profile 164
SC-16LD6.5 - Drug Profile 166
solitomab - Drug Profile 167
topotecan hydrochloride liposomal - Drug Profile 169
BMS-833923 - Drug Profile 171
XMT-1001 - Drug Profile 173
racotumomab - Drug Profile 175
MGN-1703 - Drug Profile 177
erismodegib - Drug Profile 179
Small Cell Lung Cancer Vaccine - Drug Profile 181
ME-344 - Drug Profile 182
GSK-2879552 - Drug Profile 184
OSI-930 - Drug Profile 185
AZD-1152 - Drug Profile 186
ICT-109 - Drug Profile 188
COTI-2 - Drug Profile 190
irinotecan sucrosofate liposomal - Drug Profile 193
topotecan hydrochloride - Drug Profile 196
ATT-11T - Drug Profile 197
OMN-54 - Drug Profile 198
TRBS-07 - Drug Profile 199
MDX-1110 - Drug Profile 200
ABT-737 - Drug Profile 201
Adva-27a - Drug Profile 203
COTI-219 - Drug Profile 205
(irinotecan hydrochloride + cisplatin) - Drug Profile 206
ZS-05 - Drug Profile 208
Adva-32a - Drug Profile 209
EDC-7 - Drug Profile 210
Cyt-PLAT - Drug Profile 211
PX-916 - Drug Profile 212
Peptidomimetics For Neurotensin Receptor-1 - Drug Profile 213
ADC-004 - Drug Profile 214
PF-4989216 - Drug Profile 215
Antibody Program for Cancer - Drug Profile 216
COTI-4 - Drug Profile 217
COTI-58 - Drug Profile 218
Drugs For Small Cell Lung Cancer - Drug Profile 219
CX-99 - Drug Profile 220
etoposide phosphate reformulation - Drug Profile 221
EZH2-EED Inhibitors - Drug Profile 223
THR-53 - Drug Profile 224
IBPM-002-BZ - Drug Profile 225
Small-Cell Lung Cancer - Recent Pipeline Updates 226
Small-Cell Lung Cancer - Dormant Projects 293
Small-Cell Lung Cancer - Discontinued Products 296
Small-Cell Lung Cancer - Product Development Milestones 297
Featured News & Press Releases 297
Appendix 304
Methodology 304
Coverage 304
Secondary Research 304
Primary Research 304
Expert Panel Validation 304
Contact Us 305
Disclaimer 305 List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H1 2014 16
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2014 17
Number of Products under Development by Companies, H1 2014 19
Number of Products under Development by Companies, H1 2014 (Contd..1) 20
Number of Products under Development by Companies, H1 2014 (Contd..2) 21
Number of Products under Development by Companies, H1 2014 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2014 23
Comparative Analysis by Late Stage Development, H1 2014 24
Comparative Analysis by Clinical Stage Development, H1 2014 25
Comparative Analysis by Early Stage Development, H1 2014 26
Comparative Analysis by Unknown Stage Development, H1 2014 27
Products under Development by Companies, H1 2014 28
Products under Development by Companies, H1 2014 (Contd..1) 29
Products under Development by Companies, H1 2014 (Contd..2) 30
Products under Development by Companies, H1 2014 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2014 32
Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 33
Small-Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 34
Small-Cell Lung Cancer - Pipeline by Amgen Inc., H1 2014 35
Small-Cell Lung Cancer - Pipeline by AstraZeneca PLC, H1 2014 36
Small-Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2014 37
Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 38
Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2014 39
Small-Cell Lung Cancer - Pipeline by Merck & Co., Inc., H1 2014 40
Small-Cell Lung Cancer - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 41
Small-Cell Lung Cancer - Pipeline by Aposense Ltd., H1 2014 42
Small-Cell Lung Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 43
Small-Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 44
Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2014 45
Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc., H1 2014 46
Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 47
Small-Cell Lung Cancer - Pipeline by Pfizer Inc., H1 2014 48
Small-Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 49
Small-Cell Lung Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 50
Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2014 51
Small-Cell Lung Cancer - Pipeline by Alchemia Limited, H1 2014 52
Small-Cell Lung Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014 53
Small-Cell Lung Cancer - Pipeline by Immunomedics, Inc., H1 2014 54
Small-Cell Lung Cancer - Pipeline by MEI Pharma, Inc., H1 2014 55
Small-Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 56
Small-Cell Lung Cancer - Pipeline by CytRx Corporation, H1 2014 57
Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2014 58
Small-Cell Lung Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 59
Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014 60
Small-Cell Lung Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 61
Small-Cell Lung Cancer - Pipeline by Supratek Pharma Inc., H1 2014 62
Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2014 63
Small-Cell Lung Cancer - Pipeline by TheRyte Ltd., H1 2014 64
Small-Cell Lung Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 65
Small-Cell Lung Cancer - Pipeline by Cerulean Pharma, Inc., H1 2014 66
Small-Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 67
Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 68
Small-Cell Lung Cancer - Pipeline by Neotropix, Inc., H1 2014 69
Small-Cell Lung Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2014 70
Small-Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2014 71
Small-Cell Lung Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2014 72
Small-Cell Lung Cancer - Pipeline by MolMed S.p.A., H1 2014 73
Small-Cell Lung Cancer - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2014 74
Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma, Inc., H1 2014 75
Small-Cell Lung Cancer - Pipeline by Recombio, H1 2014 76
Small-Cell Lung Cancer - Pipeline by Mycenax Biotech Inc., H1 2014 77
Small-Cell Lung Cancer - Pipeline by Polaris Group, H1 2014 78
Small-Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2014 79
Small-Cell Lung Cancer - Pipeline by centrose llc, H1 2014 80
Small-Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014 81
Small-Cell Lung Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 82
Small-Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2014 83
Small-Cell Lung Cancer - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 84
Assessment by Monotherapy Products, H1 2014 85
Assessment by Combination Products, H1 2014 86
Number of Products by Stage and Target, H1 2014 89
Number of Products by Stage and Mechanism of Action, H1 2014 94
Number of Products by Stage and Route of Administration, H1 2014 99
Number of Products by Stage and Molecule Type, H1 2014 102
Small-Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2014 231
Small-Cell Lung Cancer - Dormant Projects, H1 2014 298
Small-Cell Lung Cancer - Dormant Projects (Contd..1), H1 2014 299
Small-Cell Lung Cancer - Dormant Projects (Contd..2), H1 2014 300
Small-Cell Lung Cancer - Discontinued Products, H1 2014 301List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H1 2014 16
Number of Products under Development for Small-Cell Lung Cancer - Comparative Analysis, H1 2014 17
Number of Products under Development by Companies, H1 2014 18
Number of Products under Investigation by Universities/Institutes, H1 2014 23
Comparative Analysis by Late Stage Development, H1 2014 24
Comparative Analysis by Clinical Stage Development, H1 2014 25
Comparative Analysis by Early Stage Products, H1 2014 26
Assessment by Monotherapy Products, H1 2014 85
Assessment by Combination Products, H1 2014 86
Number of Products by Top 10 Target, H1 2014 87
Number of Products by Stage and Top 10 Target, H1 2014 88
Number of Products by Top 10 Mechanism of Action, H1 2014 92
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 93
Number of Products by Top 10 Route of Administration, H1 2014 98
Number of Products by Stage and Top 10 Route of Administration, H1 2014 99
Number of Products by Top 10 Molecule Type, H1 2014 100
Number of Products by Stage and Top 10 Molecule Type, H1 2014 101